MedPath

Effect of Unani formulation in Diabetes mellitus

Phase 3
Not yet recruiting
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2021/02/031099
Lead Sponsor
ational Institute of Unani Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients of Type-2 Diabetes mellitus taking <=2 Antihyperglycemic drugs.

Gender : Both genders

Fasting blood sugar (FBS) >= 126 mg/dl-<= 250mg/dl

Postprandial blood sugar (PPBS) >=140 mg/dl-<= 350mg/dl

HbA1c >= 6.5% - < 10%

For metabolic control:

BMI 20-35Kg/m2

Waist circumference male>=90 cm, female >=80 cm

Triglycerides <= 499 mg/dl

HDL <40-70 mg/dl

Blood Pressure SBP >= 130 mmHg, or DBP >= 85 mmHg

Exclusion Criteria

Fasting blood sugar (FBS) >250mg/dl

Postprandial blood sugar (PPBS) >350mg/dl

HbA1c < 6.5 - > 10%

Triglycerides > 499 mg/dl

HDL >70 mg/dl

Aged <30 â?? >70 years

Known cases of Type-2 Diabetes Mellitus with complications.

Pregnant & lactating Women.

History of any acute diseases or systemic illnesses.

History of any other disorders of metabolism.

Patients who are on medication > 2 antihyperglycemic drugs

changes in the type or dose of antihyperglycemic drugs treatment,

History of smoking, and alcohol abuse.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath